期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2014年晚期胃肠癌的临床研究进展 被引量：1

2014 Clinical Research Advance in Gastrointestinal Cancer
下载PDF
导出
摘要 1结直肠癌临床研究进展2014年结直肠癌（colorectal cancer,CRC）领域没有令人兴奋的突破性进展,晚期CRC患者一线靶向药物和维持治疗的选择是近年热点问题的延续,各大指南推荐全RAS检测为CRC患者使用抗表皮生长因子受体（epidermal growth factor receptor,EGFR）单抗前的必检项目。
作者 马冬
机构地区 广东省人民医院肿瘤中心胃肠肿瘤内科
出处 《循证医学》 CSCD 2015年第1期16-18,21,共4页 The Journal of Evidence-Based Medicine
关键词 胃肠肿瘤 研究进展 临床试验 gastrointestinal cancer research advances cliuical trials
分类号 R735 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1Venook AP, Niedzwieck, Lenz HI, et al. CALGB/SWOG 80405 : Phase m trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (mFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) [J]. J Clin Oncol, 2014,32(5s): Abstr LBA3.
  • 2Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE- 3): A randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2014, 15(10) : 1065-1075.
  • 3Stintzing S, Modest DP, Fischer von Weikersthal L, et al. Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK- 0306) in the final RAS evaluable population [J]. Ann Oncol, 2014, 25(suppl 4): Ahstr LBA11.
  • 4Venook A, Niedzwiecki D, Lenz H, et al. CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy[J]. Ann Oncol, 2014, 25(suppl 4): Abstr LBAI0.
  • 5Berry SR, Cosby R, Asmis T, et al. Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: A systematic review and meta-analysis[J]. Ann Oncol, 2014, Jul 23. pii: mdu272. [Epub ahead of print].
  • 6Koopman M, Simkens L, May A, et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with Capeeitabine and Bevacizumab versus observation after induction treatment with chemotherapy and Bevacizumab in metastatic colorectal cancer (mCRC)[J]. J Clin Oncol, 2014, 32(3s) : Abstr LBA388.
  • 7Koopman M, Simkens L, May AM, et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with Capecitabine + Bevacizumab versus observation after induction treatment with chemotherapy + Bevacizumab in metastatic colorectal cancer (mCRC)[J]. J Clin Oncol, 2014, 32(15s) : Abstr 3504.
  • 8Arnold D, Graeven U, Lerchenmuller CA, et al. Maintenance strategy with Fluoropyrimidines (FP) plus Bevaeizumab (Bey), Bey alone, or no treatment, following a standard combination of FP, Oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase 111 non-inferiority trial (AIO KRK 0207) [J]. J Clin Oncol, 2014, 32(15s) : Abstr 3503.
  • 9Hegewisch-Becker S, Graeven U, Lerchenmtlller C, et al. Maintenance strategy with Fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone or no treatment, following a 24- week first-line induction with FP, Oxaliplatin (Ox) and Bey for patients with metastatic colorectal cancer: Mature data and subgroup analysis of the Aio Krk 0207 phase ill study[J]. Ann Oncol, 2014, 25 (4s): Abstr 4980.
  • 10Chibaudel B, Toumigand C, Samson B, et al. Bevacizumab- Erlotinib as maintenance therapy in metastatic colorectal cancer. Final results of the GERCOR DREAM study [J]. Ann Oncol, 2014, 25 (4s) : Abstr 4970.

同被引文献9

引证文献1

二级引证文献3

循证医学
2015年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部